A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
Key claim: This early-phase trial evaluates the safety, tolerability, pharmacokinetics, and effects on anemia and MF symptoms of elritercept administered alone or in combination with ruxolitinib in adults with myelofibrosis.
Abstract
The main aim of this study is to learn how safe elritercept is and how well it is tolerated when taken alone and in combination with the JAK inhibitor, ruxolitinib. Other aims are to learn about the effects of elritercept on the signs and symptoms of MF when taken with or without ruxolitinib and to learn how elritercept affects the body, how the body processes elritercept, and the effects of elritercept on anemia when taken with or without ruxolitinib The study will also check on how safe elritercept is and how well it is tolerated.
Why this matters
Anemia is a major upstream driver of fatigue in myelofibrosis, and elritercept (an activin/TGF-β superfamily ligand trap) represents a novel mechanism distinct from ESAs, luspatercept, and repurposed agents like nelfinavir. If effective, it could expand the supportive-care armamentarium for the anemia-fatigue axis and offer a combination partner for ruxolitinib in patients whose JAK inhibition exacerbates cytopenias.